Back to news

Roivant Sciences rises after positive Phase 3 uveitis trial results

Investivoq PriceTracker

Roivant Sciences (ROIV) is up 6.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst is a fresh clinical update showing brepocitinib delivered positive Phase 3 results in two late-stage trials for non-infectious uveitis. That kind of readout can matter because it may expand the drug’s commercial opportunity and gives investors a clearer path toward another regulatory filing.

Details:

  • Roivant disclosed positive topline data on October 21, 2026 from the Phase 3 CLARITY-1 and CLARITY-2 studies run by Priovant, its subsidiary focused on brepocitinib.
  • Both trials met the primary endpoint, with materially lower treatment failure rates than placebo through 48 weeks, alongside success on key secondary measures.
  • The company said Priovant intends to submit a supplemental NDA for non-infectious uveitis in the first half of 2027, which points to a potential next step toward label expansion.
  • Roivant also announced it will report fiscal second-quarter results on November 9, 2026 and host an investor day on December 9, 2026, which may have added to investor attention, though the trial news appears to be the main driver.

    • Sources:

    SEC, Roivant Sciences

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $ROIV Insider Trading Activity

    ROIV Insider Trades

    $ROIV insiders have traded $ROIV stock on the open market 42 times in the past 6 months. Of those trades, 0 have been purchases and 42 have been sales.

    Here’s a breakdown of recent trading of $ROIV stock by insiders over the last 6 months:

    • MAYUKH SUKHATME (President & CIO) has made 0 purchases and 9 sales selling 2,000,000 shares for an estimated $70,626,215.
    • KEITH S MANCHESTER has made 0 purchases and 6 sales selling 1,638,163 shares for an estimated $56,444,075.
    • FINANCIAL LP QVT has made 0 purchases and 5 sales selling 1,438,163 shares for an estimated $49,354,075.
    • DANIEL ALLEN GOLD has made 0 purchases and 5 sales selling 1,438,163 shares for an estimated $49,354,075.
    • ERIC VENKER (President & Immunovant CEO) has made 0 purchases and 7 sales selling 1,000,000 shares for an estimated $34,152,660.
    • MELISSA B, EPPERLY has made 0 purchases and 6 sales selling 40,438 shares for an estimated $1,447,342.
    • MEGHAN FITZGERALD has made 0 purchases and 4 sales selling 35,112 shares for an estimated $1,350,152.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive ROIV Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $ROIV Hedge Fund Activity

    We have seen 301 institutional investors add shares of $ROIV stock to their portfolio, and 173 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • MORGAN STANLEY removed 9,235,420 shares (-17.8%) from their portfolio in Q2 2026, for an estimated $326,841,513
    • GOLDMAN SACHS GROUP INC added 7,444,867 shares (+67.0%) to their portfolio in Q2 2026, for an estimated $263,473,843
    • UBS GROUP AG removed 5,152,831 shares (-22.8%) from their portfolio in Q2 2026, for an estimated $182,358,689
    • BLACKROCK, INC. added 3,981,831 shares (+9.0%) to their portfolio in Q2 2026, for an estimated $140,916,999
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 3,715,594 shares (+inf%) to their portfolio in Q2 2026, for an estimated $131,494,871
    • POINT72 ASSET MANAGEMENT, L.P. added 3,582,578 shares (+402.1%) to their portfolio in Q2 2026, for an estimated $126,787,435
    • NATIONAL BANK OF CANADA /FI/ removed 3,524,126 shares (-56.0%) from their portfolio in Q2 2026, for an estimated $124,718,819

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $ROIV Price Targets

    Multiple analysts have issued price targets for $ROIV recently. We have seen 4 analysts offer price targets for $ROIV in the last 6 months, with a median target of $38.5.

    Here are some recent targets:

    • Yatin Suneja from Guggenheim set a target price of $36.0 on 05/26/2026
    • Douglas Tsao from HC Wainwright & Co. set a target price of $34.0 on 05/21/2026
    • Yaron Werber from TD Cowen set a target price of $41.0 on 05/21/2026
    • Samantha Semenkow from Citigroup set a target price of $42.0 on 05/21/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.